Loading...
Market
When will the first patient be enrolled in Phase I/II clinical trial of REC-1245?
2
Resolution / Starting Odds
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 or later • 25%
Press releases from Recursion Pharmaceuticals or clinical trial registry updates
Story
Recursion's AI-Derived REC-1245 Gets FDA Clearance; First-in-Class RBM39 Degrader for Solid Tumors, Lymphoma
Oct 2, 2024, 12:20 PM
Recursion Pharmaceuticals (RXRX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader intended for biomarker-enriched solid tumors and lymphoma. This marks the company's first program to combine its end-to-end suite of AI-enabled active learning modules, moving from target identification to IND enabling studies in under 18 months, more than twice as fast as industry standards. The FDA clearance paves the way for Recursion to initiate a Phase I/II clinical trial of REC-1245.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Before July 2025 • 25%
July 2025 to December 2025 • 25%
2026 or later • 25%
Never • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%